Franklin Street Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Franklin Street Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,450	Closed	-$735K	–	176
2016 Q4	$735K	Sell	10,450 -50	-0.5%	-$3.55K	0.13%	106
2016 Q3	$745K	Sell	10,500 -790	-7%	-$50.4K	0.14%	110
2016 Q2	$552K	Sell	11,290 -145	-1%	-$9.38K	0.1%	125
2016 Q1	$724K	Sell	11,435 -20	-0.2%	-$1.31K	0.14%	118
2015 Q4	$1.28M	Hold	11,455	–	–	0.25%	103
2015 Q3	$1.1M	Sell	11,455 -510	-4%	-$58.4K	0.22%	110
2015 Q2	$1.23M	Sell	11,965 -410	-3%	-$31.8K	0.22%	106
2015 Q1	$768K	Hold	12,375	–	–	0.14%	124
2014 Q4	$543K	Sell	12,375 -2,550	-17%	-$117K	0.1%	129
2014 Q3	$845K	Sell	14,925 -800	-5%	-$40.3K	0.16%	125
2014 Q2	$706K	Buy	15,725 +1,525	+11%	+$62.8K	0.13%	147
2014 Q1	$694K	Buy	+14,200	New	+$731K	0.14%	150

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

CGT

Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Franklin Street Advisors's RARE Position: Q1 2017 in Review

Franklin Street Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2017, closing a stake of 10,450 shares — an estimated $735K sold.

Franklin Street Advisors first reported a position in RARE in Q1 2014 and held it in 12 quarters. The position peaked at $1.28M in Q4 2015. 164 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

Franklin Street Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q1 2017 after selling out during the quarter.
Franklin Street Advisors sold 10,450 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $735K.
Franklin Street Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 12 quarters.
Franklin Street Advisors's Ultragenyx Pharmaceutical position peaked at $1.28M in Q4 2015.
164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on Franklin Street Advisors's 13F filing for Q1 2017, filed 4 Apr 2017.